|
FR2551758B1
(fr)
*
|
1983-08-16 |
1986-01-31 |
Anvar |
Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
|
|
US4650771A
(en)
*
|
1983-11-04 |
1987-03-17 |
Miles Laboratories, Inc. |
Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
|
|
US4595656A
(en)
*
|
1984-01-06 |
1986-06-17 |
Becton Dickinson & Company |
Coupling agents and products produced therefrom
|
|
US4654311A
(en)
*
|
1984-06-15 |
1987-03-31 |
Syntex (U.S.A.) Inc. |
Serum pretreatment for digoxin assay
|
|
US4767720A
(en)
*
|
1985-08-29 |
1988-08-30 |
Hsc Research Development Corporation |
Antidigoxin antibodies
|
|
US5013720A
(en)
*
|
1986-05-06 |
1991-05-07 |
Abbott Laboratories |
SAP-6-Val proteins and methods
|
|
FR2601141A1
(fr)
*
|
1986-07-02 |
1988-01-08 |
Centre Nat Rech Scient |
Produit de couplage a base d'haptene, utile notamment comme substance immunogene, anticorps correspondants et applications
|
|
US5034317A
(en)
*
|
1987-01-30 |
1991-07-23 |
Polaroid Corporation |
Enzyme controlled release system and organic conjugate reactant
|
|
US6326136B1
(en)
*
|
1988-04-01 |
2001-12-04 |
Digene Corporation |
Macromolecular conjugate made using unsaturated aldehydes
|
|
DE3836656A1
(de)
*
|
1988-10-27 |
1990-05-03 |
Boehringer Mannheim Gmbh |
Neue digoxigenin-derivate und ihre verwendung
|
|
CA2031109C
(en)
*
|
1990-07-27 |
1992-01-28 |
Susan J. Danielson |
Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
|
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
RU2132553C1
(ru)
*
|
1996-05-30 |
1999-06-27 |
Ивановская Елена Алексеевна |
Количественное определение дигоксина в сыворотке крови методом инверсионной вольтамперометрии
|
|
WO1998036099A1
(en)
*
|
1997-02-18 |
1998-08-20 |
Oncor, Inc. |
Detection of targets with green fluorescent protein and fluorescent variants thereof
|
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
ATE329622T1
(de)
*
|
1998-04-15 |
2006-07-15 |
Lexigen Pharm Corp |
Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
|
|
RU2262510C9
(ru)
*
|
1999-05-19 |
2006-04-20 |
Лексиген Фармасьютикэлс Корп. |
Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US7517526B2
(en)
*
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
EP1366067B1
(en)
*
|
2001-03-07 |
2012-09-26 |
Merck Patent GmbH |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DE60239454D1
(de)
*
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
|
ATE542137T1
(de)
*
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
ES2358737T3
(es)
*
|
2002-01-31 |
2011-05-13 |
Randox Laboratories Ltd. |
Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos.
|
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
|
BRPI0317376B8
(pt)
*
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
|
US7935539B2
(en)
*
|
2003-02-14 |
2011-05-03 |
Siemens Healthcare Diagnostics, Inc. |
Generic method for latex agglutination assays
|
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
JP2005172694A
(ja)
*
|
2003-12-12 |
2005-06-30 |
Fuji Photo Film Co Ltd |
タンパク質の検出方法
|
|
EP1699822B1
(en)
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
|
PT1699821E
(pt)
*
|
2003-12-31 |
2012-08-23 |
Merck Patent Gmbh |
Proteína de fusão fc-eritropoietina com farmacocinética melhorada
|
|
JP2007517506A
(ja)
*
|
2004-01-05 |
2007-07-05 |
イーエムディー・レキシゲン・リサーチ・センター・コーポレーション |
標的化用化合物
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
RU2437893C2
(ru)
*
|
2004-12-09 |
2011-12-27 |
Мерк Патент Гмбх |
Варианты il-7 со сниженной иммуногенностью
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
CA2656347A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
|
ES2491743T3
(es)
|
2006-11-01 |
2014-09-08 |
Ventana Medical Systems, Inc. |
Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
|
|
US7682789B2
(en)
*
|
2007-05-04 |
2010-03-23 |
Ventana Medical Systems, Inc. |
Method for quantifying biomolecules conjugated to a nanoparticle
|
|
EP3561513A1
(en)
|
2007-05-23 |
2019-10-30 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
AU2009256349B2
(en)
|
2008-06-05 |
2014-06-26 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
|
WO2010065437A1
(en)
|
2008-12-03 |
2010-06-10 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
|
WO2010121766A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
USPP22463P3
(en)
*
|
2010-02-16 |
2012-01-17 |
Menachem Bornstein |
Gypsophila plant named ‘Pearl Blossom’
|
|
CA2800936A1
(en)
|
2010-07-02 |
2012-01-05 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
MX2013007559A
(es)
*
|
2011-01-03 |
2013-07-29 |
Hoffmann La Roche |
Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido.
|
|
AU2012294814A1
(en)
|
2011-08-05 |
2014-02-27 |
Research Development Foundation |
Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
|
|
EP2912064B1
(en)
|
2012-10-24 |
2019-04-24 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
|
EP3036005A4
(en)
|
2013-08-21 |
2017-04-26 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeting connexin hemichannels
|
|
CA3004504A1
(en)
|
2015-11-06 |
2017-05-11 |
Ventana Medical Systems, Inc. |
Tissue homogenisation for representative diagnostics
|
|
KR102815803B1
(ko)
|
2015-12-02 |
2025-06-05 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
|
AU2017241440B2
(en)
|
2016-03-29 |
2024-06-27 |
Board Of Regents, The University Of Texas System |
Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
CN109195990A
(zh)
|
2016-03-30 |
2019-01-11 |
Musc研究发展基金会 |
通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
|
|
US11746152B2
(en)
|
2016-07-20 |
2023-09-05 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
|
|
JP7768666B2
(ja)
|
2017-05-31 |
2025-11-12 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
|
CN111148762A
(zh)
|
2017-05-31 |
2020-05-12 |
斯特库伯株式会社 |
免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
|
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
|
WO2019055825A1
(en)
|
2017-09-15 |
2019-03-21 |
The Regents Of The University Of California |
INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
|
|
CA3081548A1
(en)
|
2017-09-26 |
2019-04-04 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2019092269A1
(en)
|
2017-11-13 |
2019-05-16 |
F. Hoffmann-La Roche Ag |
Devices for sample analysis using epitachophoresis
|
|
JP7455816B2
(ja)
*
|
2018-09-20 |
2024-03-26 |
ヴェンタナ メディカル システムズ, インク. |
クマリン系架橋試薬
|
|
WO2020074742A1
(en)
|
2018-10-12 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
Detection methods for epitachophoresis workflow automation
|
|
CN110174363A
(zh)
*
|
2019-01-09 |
2019-08-27 |
北京九强生物技术股份有限公司 |
6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
|
|
US20220325268A1
(en)
|
2019-05-14 |
2022-10-13 |
Roche Sequencing Solutions, Inc |
Devices and methods for sample analysis
|
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
CN113736744B
(zh)
*
|
2021-10-14 |
2023-07-18 |
江南大学 |
洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用
|